3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Gynecologic
4
Breast
3
Thoracic
1
Sarcoma
1
Head & Neck
1
Gastrointestinal
1
Dermatologic
1
Conditions
Rectal Neoplasms
4
Colorectal Neoplasms
4
Colonic Neoplasms
4
Liver Neoplasms
3
Carcinoma, Hepatocellular
3
Precancerous Conditions
2
Pancreatic Neoplasms
2
Esophageal Neoplasms
2
Adenocarcinoma Of Esophagus
2
Small Cell Lung Carcinoma
1
Ovarian Neoplasms
1
Lung Neoplasms
1
Gallbladder Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Cholangiocarcinoma
1
Carcinoma, Ovarian Epithelial
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Biliary Tract Neoplasms
1
Adenomatous Polyps
1
Interventions
pembrolizumab
50
Cyclophosphamide
25
Carboplatin
25
Gemcitabine
20
Cisplatin
19
fludarabine
18
Nivolumab
17
Paclitaxel
16
Bevacizumab
15
Specimen Handling
14
Fluorouracil
11
Magnetic Resonance Spectroscopy
10
aldesleukin
9
Oxaliplatin
9
Irinotecan
9
Docetaxel
9
Biopsy
9
olaparib
8
Trastuzumab
8
durvalumab
7
atezolizumab
7
Hyperthermic Intraperitoneal Chemotherapy
7
Albumin-Bound Paclitaxel
7
Taxes
6
Leucovorin
6
Ipilimumab
6
Interleukin-2
6
Cetuximab
6
Capecitabine
6
130-nm albumin-bound paclitaxel
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Ovarian Neoplasms
×
Mass Spectrometry
×
Gastrointestinal
×
Clear all
NCT00900094
2012-02-07
IRB 2000-294
University of Michigan Rogel Cancer Center
Completed
200 enrolled